Regeneron Pharmaceuticals Inc.
Tarrytown, NY
- UEI
- N3F9MH7E6HD6
- CAGE
- 544P9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 777 Old Saw Mill River Rd, Tarrytown, NY 10591, USA
- Website
- regeneron.com
- Founded
- 1988
- Employees
- 10K-50K
- Estimated annual revenue
- $10B+
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $279,399,593 |
| FY2025 | -$331,708,160 |
| FY2024 | $0 |
| FY2023 | $326,475,488 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $279,399,593 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Production of targeted null mutations for 10,000 genes in C57BL/6 ES cells | National Institutes of Health | $14,862,829 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Pfizer Inc. | New York, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Cardinal Health, Inc. | — | — |
| Amgen Inc. | Thousand Oaks, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Exela Pharma Sciences LLC | Lenoir, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Amerisourcebergen | Carrollton, TX | 424210 Drugs and Druggists' Sundries Merchant Wholesalers |
About the company
Products and Services
The government contractor in question primarily provides pharmaceuticals and drugs, as well as therapeutic production services. The products range from specific drugs like EVKEEZA to large-scale production of therapeutics for national emergencies, such as the COVID-19 pandemic. Over time, the contractor has expanded its services from supplying specific pharmaceutical products to large-scale production of therapeutics.
Customers
The contractor has been awarded contracts by various government agencies, including the Department of Veterans Affairs (VA), the Department of Defense (DOD) - specifically the Army and the USASC, and the Department of Health and Human Services (HHS). Over time, the contractor has expanded its customer base from the VA and HHS to include the DOD. The top buyers from this contractor are the DOD and HHS, given the high value of the contracts awarded by these agencies. The contractor's awards are associated with set-asides such as the Operation Warp Speed (OWS) for COVID-19 response.
Vehicles
The contract vehicles under which this contractor is awarded include BPA Call, Definitive Contract, and Delivery Order. Over time, the contractor has been awarded increasingly larger contracts, moving from Delivery Orders to Definitive Contracts and BPA Calls, indicating an expansion in the scale of the contractor's operations.
Summary
The contractor has shown a trend of expanding its services and customer base over time. It has moved from supplying specific pharmaceutical products to large-scale production of therapeutics, and from serving the VA and HHS to include the DOD. The contractor's awards are associated with significant national responses, such as the COVID-19 pandemic.
Data
The analysis is based on seven contracts awarded between 09/27/13 and 11/24/21.
Quick answers
Is Regeneron Pharmaceuticals Inc. registered in SAM.gov?
Yes. Regeneron Pharmaceuticals Inc.'s SAM.gov registration is active through October 9, 2027.
Which contract vehicles does Regeneron Pharmaceuticals Inc. hold?
Regeneron Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Regeneron Pharmaceuticals Inc. received in federal contracts?
Federal contracts obligated $274,166,921 to Regeneron Pharmaceuticals Inc. in fiscal years 2023 through 2027.
What is Regeneron Pharmaceuticals Inc.'s most recent federal award?
Regeneron Pharmaceuticals Inc.'s most recent federal contract award is Evkeeza drug (36C24122N0160), from Veterans Integrated Service Network 1 (VHA), on November 24, 2021.
On GovTribe
See Regeneron Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors